InvestorsHub Logo
Followers 0
Posts 178
Boards Moderated 0
Alias Born 11/19/2017

Re: None

Sunday, 06/24/2018 2:13:34 PM

Sunday, June 24, 2018 2:13:34 PM

Post# of 43784
In 10Q cvm said they only have $10.5m potential costs remaining for mgmt of p3 trial. Ergomed is committed to $12m to study for a single digit % royalty. R&D costs keep reducing with brunt of multikine cost done. From warrant cash raise we're looking solid. Now if they win arb that will supply funds to manufacture with FDA approval.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News